Nebramine

The drug selection for patients with neurological diseases has long been limited by the insufficient precision of drug action targets. As a novel peripheral κ-opioid receptor agonist, nirabulam exerts an analgesic effect by selectively activating κ-opioid receptors in peripheral nerves, and can avoid the common central nervous system adverse reactions common to traditional opioids. It is clinically mainly used for the symptomatic treatment of chronic pain and osteoarthritis-related pain, and is especially suitable for adult patients who require long-term analgesia and have low tolerance to the central side effects of opioids. Its property of not penetrating the blood-brain barrier greatly reduces the risks of addiction, respiratory depression and others, providing a safer medication path for chronic pain management.

At present, the global nirabulam-related market is still in the early stage of development, and there is no publicly verifiable unified market size data. Due to the clear clinical advantages of this drug and the large base of the population covered by its indications, a number of pharmaceutical companies have laid out related pipelines. With the subsequent progress of clinical data and product launch, its market growth potential is worthy of attention.

The leading in-development product of nirabulam was originally developed by Trevena Inc. in the United States, with the original research trade name Olinvyk. The core compound patent of it expires in the United States in 2033. The main approved dosage form at present is injection, with specifications of 1mg/2mL and 10mg/20mL, which has been included in the FDA Reference Listed Drug Catalog. Up to now, no nirabulam preparation has been approved for marketing in China, and no enterprise has submitted the CDE registration information for this API. (Data as of October 2024, please refer to the official CDE website for the latest information.)

CATO provides a full set of impurity reference standards for nirabulam API. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. They meet the compliance requirements of multiple regulations including the Chinese Pharmacopoeia and FDA, and can fully meet the use needs of various reference standards in the stages of drug research and development and quality research.